Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Pasteur's India Arm Shantha Biotech Bags WHO Supply Contract For Pentavalent Vaccines

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Shantha Biotechnics - the Indian biotech acquired by Sanofi-Aventis - has bagged a $340 million contract from the World Health Organization for supply of the pentavalent vaccine branded SHAN5 over a period of two years starting 2010. The vaccine indigenously developed by Shantha immunizes children against diphtheria, pertussis, tetanus, hemophillus influenza B and hepatitis B

You may also be interested in...



India Tightens Income Tax Noose On Sanofi-Aventis' Shantha Biotech Deal

India's tax authority claims it is owed for capital gains on the deal between two French companies because it was an Indian company that changed hands.

India Tightens Income Tax Noose On Sanofi-Aventis' Shantha Biotech Deal

India's tax authority claims it is owed for capital gains on the deal between two French companies because it was an Indian company that changed hands.

WHO Does What It Warned: Delists Shantha Biotech's Pentavalent Vaccine Shan5; More Pains For Sanofi-Aventis?

MUMBAI - In a move that could in the short term severely impair the reputation of Hyderabad-based vaccines maker Shantha Biotechnics, now part of Sanofi-Aventis, the World Health Organization has delisted its popular pentavalent vaccine Shan5, which is used by scores of nations as part of their national immunization programs for the prevention against deadly diseases like diphtheria, tetanus, hepatitis B and Hib

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC072929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel